Chronic Obstructive Pulmonary Disease Market Size to Hit USD 40.39 Billion by 2035 | SNS Insider

The U.S. COPD market is projected to rise from $6.93B in 2025 to $10.93B by 2035 (+$4.00B), with Europe expanding from $7.02B to $10.98B (+$3.96B). Growth is attributed to higher COPD diagnoses, adoption of combination therapies/biologics, and increasing digital respiratory care usage.

Analysis

This is a mid-single-digit CAGR story, which means the equity upside is not in the headline TAM expansion itself but in who captures the mix shift. The best positioned names are the large respiratory franchises with existing distribution, payer access, and the ability to move patients from generic bronchodilator/controller therapy into higher-margin triple therapy or biologic segments; that favors GSK, AZN, and to a lesser extent SNY over smaller single-product respiratory assets.

The second-order loser set is generic inhaler and low-cost maintenance therapy suppliers, but the bigger constraint is payer behavior: diagnosis expansion does not automatically translate into pricing power. In the U.S., step edits and adherence gaps can keep realized revenue below modelled market growth, while in Europe tendering and HTA can turn volume growth into flat ASPs. If digital respiratory care improves persistence, it helps branded incumbents more than it creates a standalone profit pool.

Catalysts are mostly 1-3 months of earnings and label/data read-throughs, with the structural upside unfolding over 6-18 months as diagnosed prevalence rises. The contrarian risk is that consensus is overestimating monetization: COPD is a chronic, older population with high churn and cost sensitivity, so the market can grow while margins stagnate. The thesis breaks if biologic uptake disappoints, payer restrictions tighten, or respiratory growth comes with higher rebate burden than expected.

Key Decisions for Investors

• Long GSK on pullbacks as the cleanest way to express COPD mix expansion over 6-12 months; use a relative-value frame versus XLV or PFE, and cut if respiratory revenue guidance fails to accelerate.
• Long AZN with a 6-18 month horizon; the risk/reward improves if respiratory share gains are reaffirmed in upcoming results, but the trade should be reduced if U.S. formulary access softens or rebates rise faster than volume.
• Long SNY as a smaller, higher-beta exposure to biologic-driven COPD adoption; best suited for a catalyst window around pipeline updates, with downside if COPD label expansion/uptake stalls.
• Avoid chasing generic respiratory proxies; if you want a hedge, short a generic pharma basket (e.g. VTRS/TEVA only if respiratory exposure is meaningful in your basket) against GSK/AZN longs, since branded share capture is the real variable.
• Use 6-12 month call spreads rather than near-dated calls if you want convexity in GSK or AZN; the fundamental re-rating is gradual, and near-term theta is likely to overwhelm the pace of TAM recognition.